Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01MAU
|
|||
| Former ID |
DIB013153
|
|||
| Drug Name |
AZD-1446
|
|||
| Synonyms |
TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Targacept Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13ClN2O2
|
|||
| Canonical SMILES |
C1C2CN(CC2CN1)C(=O)C3=CC=C(O3)Cl
|
|||
| InChI |
1S/C11H13ClN2O2/c12-10-2-1-9(16-10)11(15)14-5-7-3-13-4-8(7)6-14/h1-2,7-8,13H,3-6H2/t7-,8+
|
|||
| InChIKey |
GTUIQNHJSXQMKW-OCAPTIKFSA-N
|
|||
| CAS Number |
CAS 1025007-04-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01012375) Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.. U.S. National Institutes of Health. | |||
| REF 2 | A randomized, double-blind, placebo-controlled crossover study of 4 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl). 2014 Mar;231(6):1251-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.